![](/img/cover-not-exists.png)
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Jimeno, A., Shirai, K., Choi, M., Laskin, J., Kochenderfer, M., Spira, A., Cline-Burkhardt, V., Winquist, E., Hausman, D., Walker, L., Cohen, R. B.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu574
Date:
March, 2015
File:
PDF, 152 KB
english, 2015